460367-82-2

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 4-ethoxypiperidine-1-carboxylate is used as a chemical intermediate for the synthesis of various pharmaceutical drugs. Its role in the production process is crucial for creating the final drug products, as it serves as a building block in the chemical reactions that lead to the formation of the desired active pharmaceutical ingredients (APIs). Understanding its safety, potential hazards, and proper handling methods is essential for ensuring the safe and effective production of these medications.

Upstream product

• 75-03-6 ethyl iodide 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1122-86-7 4-ethoxypiperidine 

Relevant academic research and scientific papers

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS

Chroman derivatives according to Formula (I) below: wherein R1, R2, R3 ,and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical .compositions containing a